If you have been reading about electron paramagnetic resonance and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-21. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
== History == Since its discovery in 1967, serine protease DPP-4 has been a popular subject of research. Inhibitors of DPP-4 have long been sought as tools to elucidate the functional significance of the enzyme. The first inhibitors were characterized in the late 1980s and 1990s. Each inhibitor was important to establish an early structure activity relationship (SAR) for subsequent investigation. The inhibitors fall into two main classes, those that interact covalently with DPP-4 and those that do not. DPP-4 is a dipeptidase that selectively binds substrates that contain proline at the P1-position, thus many DPP-4 inhibitors have 5-membered heterocyclic rings that mimic proline, e.g. pyrrolidine, cyanopyrrolidine, thiazolidine and cyanothiazolidine. These compounds commonly form covalent bonds to the catalytic residue Ser630. In 1994, researchers from Zeria Pharmaceuticals unveiled cyanopyrrolidines with a nitrile function group that was assumed to form an imidate with the catalytic serine. Concurrently other DPP-4 inhibitors without a nitrile group were published but they contained other serine-interacting motifs, e.g. boronic acids, phosphonates or diacyl hydroxylamines. These compounds were not as potent because of the similarity of DPP-4 and prolyl oligopeptidase (PEP) and also suffered from chemical instability. Ferring Pharmaceuticals filed for patent on two cyanopyrrolidine DPP-4 inhibitors, which they published in 1995. These compounds had excellent potency and improved chemical stability. In 1995, Edwin B.
== Education and career == Zubarev earned a Master of Science in Applied Physics at Moscow Engineering Physics Institute in 1986. He obtained a PhD in ion physics from Uppsala University in 1997, supervised by Bo Sundqvist. After his doctorate, he worked at Cornell University, where in 1997 he co-discovered electron-capture dissociation (ECD) of polypeptides with Fred McLafferty. He later held posts at the University of Southern Denmark and Uppsala University, before becoming professor of medicinal proteomics at Karolinska Institutet.
== Release == Valve announced Half-Life: Alyx in November 2019. They waited until it was almost complete before announcing it, aiming to avoid the delays of previous games. They were conscious that players, having waited years for a new Half-Life game, might be disappointed by a VR game, and tightly managed the announcement. To promote Alyx, Valve made the prior Half-Life games free on Steam from January 2020 until its release. Valve was due to showcase Alyx at the 2019 Game Awards that December, but canceled hours prior, saying they were "hard at work on the game". Alyx was released on March 23, 2020. It was free to owners of Valve Index headsets or controllers. Valve released a Linux version on May 15, along with Vulkan rendering support for both platforms. A pre-release build was mistakenly released on Steam; it included non-VR developer tools, allowing interactions such as picking up objects and firing weapons. However, most basic interactions, such as pressing buttons or filling Alyx's backpack, could not be completed with mouse-and-keyboard controls. Asked about plans for future Half-Life games, the designer David Speyrer said Valve was willing but were waiting for the reaction to Alyx. Walker said "we absolutely see Half-Life: Alyx as our return to this world, not the end of it". Alyx is included with all Steam Frame headsets, a standalone VR headset released by Valve in September 2026. Valve ported Alyx to run on the Steam Frame's ARM64 processor and optimized it with foveated rendering, whereby resolution is reduced in areas the player is not looking at.
Sources: en.wikipedia.org
post-mastectomy re-creation of the breast(s); trauma damage (blunt, penetrating), disease (breast cancer), and explantation deformity (empty breast-implant socket). congenital defect correction: micromastia, tuberous breast deformity, and Poland's syndrome. primary augmentation: the aesthetic enhancement (contouring) of the size, form, and feel of the breasts. The application of the adipose fat tissue as autologous filler for injection to correct bodily defects and for breast augmentation was developed by Melvin Bircoll by way of the fat-injection method. In 1987, the surgeon Eduardo Krulig injected fat-grafts with a syringe and a blunt-tip needle, and also used a disposable fat trap to facilitate the collection of body fat and to ensure the sterility of the harvested adipocyte tissue. The doctors J. Newman and J. Levin designed a lipo-injector gun with a gear-driven plunger for the even injection of autologous fat-tissue to the breast-implant pocket. The design of the lipo-injector gun featured a ratchet-gear for accurately emplacing the fat-grafts to the breast-implant pocket; the trigger action injected 0.1 cm3 of filler. Non-surgical, fat-graft augmentations of the breast employs adipocyte fat from elsewhere in the body of the woman (up to 300 ml of body fat) with three injections of equal volume, is injected to the subpectoral space and to the intrapectoral space of the pectoralis major muscle, and to the submammary space in order to achieve a breast of natural appearance and contour.
=== Gene therapy === Gene therapy was first trialled in 2014 on a single patient, and followed by clinical trials in which several patients were successfully treated. In 2023, both exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) were approved for the treatment of sickle cell disease. Kendric Cromer in October 2024 became the first commercial case in the US to receive gene therapy and was discharged from Children's National Hospital. The one-off gene-editing therapy, Casgevy, also known as Exa-cel, is to be offered to patients on the National Health Service (NHS) in England as from 2025. Both Casgevy and Lyfgenia work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel, the person with sickle cell disease's bone marrow undergoes a myeloablation procedure to destroy the remaining HSCs. The treated cells are then infused back into the patient, where they colonise the bone marrow and eventually resume production of blood cells. Casgevy works by editing the BCL11A gene, which normally inhibits haemoglobin F (foetal haemoglobin) production in adults. The edit increases HbF production, which is not prone to sickling. Lyfgenia introduces a new gene for T87Q-globin, which coexists with the sickling beta-globin but reduces the incidence of sickling. A study published in the New England Journal of Medicine in April 2026 showed a new CRISPR gene therapy labeled renizgamglogene autogedtemcel (abbreviated to reni-cel) that increased total hemoglobin from 9.8 to 13.8g/dL.
Rosett (1953), dean of the University of Chicago Booth School of Business, Arts and Sciences at Washington University in St. Louis, and chairman of National Bureau of Economic Research Robert L. Friedheim (1955), former director of the USC School of International Relations Calvin B. T. Lee (1955), former chancellor of University of Maryland, Baltimore County and acting president of Boston University Robert E. Paaswell (1956), civil engineer, former interim president of City College of New York and CEO of Chicago Transit Authority Kenneth Gros Louis (1959), chancellor of Indiana University system Richard A. Merrill (1959), 7th dean of the University of Virginia School of Law Stephen Joel Trachtenberg (1959), president of the University of Hartford and of George Washington University David C. Levy (1960), dean of the Parsons School of Design and president of the Corcoran Gallery of Art Steven M. Cahn (1966), provost and acting president of Graduate Center of the City University of New York Dimitri B. Papadimitriou (1970), executive vice president and provost of Bard College David Rubin (1970), professor of communications and dean of S. I. Newhouse School of Public Communications Alan Cooper (1971), provost of Jewish Theological Seminary of America, former member of Sha Na Na William Germano (1972), dean of the faculty of humanities and social sciences at Cooper Union, former editor-in-chief of Columbia University Press Saul Levmore (1973), commercial law scholar, former dean of the University of Chicago Law School Ronald Mason Jr.
Between her second and third flights, Caldwell Dyson continued to work inside Houston’s Mission Control Center as CAPCOM for both space shuttle and space station operations, serving as the lead CAPCOM for various ISS missions, including the lead and development of the CAPCOM cadre for Boeing Starliner Mission Operations team. She was also the ground IV for US EVA 32, performed by Scott Kelly and Kjell Lindgren. Caldwell Dyson initiated and led several projects to improve training and operations aboard the ISS, most notably developing the EVA Qualification training flow (EVQ) for astronaut candidates. After her third trip to space, she served as the ground IV for US EVA 95, performed by Jessica Meir and Christopher Williams in March 2026. She also worked as one of the CAPCOM for the Artemis II mission, working during 3 separate shifts. During the summer 2026 with the European Space Agency, she participated in the CAVES training program with her NASA astronaut colleague, Ben Bailey and astronauts from other agencies John McFall, Ayu Yoneda and Rosemary Coogan. As Tracy Dyson, she is the host of a series on NASA TV called StationLife, which focuses on facets of life aboard the International Space Station. On March 21, 2017, Caldwell Dyson stood behind President Trump as he signed a bill for NASA to send humans to Mars in the 2030s and receive $19.5 billion in 2018 funding. Caldwell Dyson and fellow NASA astronaut Chris Cassidy presented Trump with an official flight jacket during the ceremony.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.